We will contribute to the development of a point-of-care (PoC) COVID-19 test by providing novel technology to alter antigen structure and enhance the sensitivity of PoC tests that can be monitored by biolayer interferometry.
We have commenced a large project to express both the spike and nucleoproteins of COVID-19 and other coronaviruses including SARS, MERS, OC43, 229E, NL63, and HKU1. The antigens will be provided to Burnet’s Global Health Diagnostics Development Group for development of a COVID-19 point-of-care (PoC) diagnostic test.
Funding
Partners
- Victorian Government (part of $1m for Diagnostics Development)
Project
Team
Meet the project team. Together, we are translating research into better health, for all.
